Frontiers in Immunology,
Journal Year:
2023,
Volume and Issue:
14
Published: Dec. 21, 2023
Epstein-Barr
virus
(EBV)
is
a
prevalent
oncogenic
estimated
to
infect
greater
than
90%
of
the
world's
population.
Following
initial
infection,
it
establishes
latency
in
host
B
cells.
EBV
has
developed
multitude
techniques
avoid
detection
by
immune
system
and
establish
lifelong
infection.
T
cells,
as
important
contributors
cell-mediated
immunity,
make
an
attractive
target
for
these
immunoevasive
strategies.
Indeed,
evolved
numerous
mechanisms
modulate
cell
responses.
For
example,
can
augment
expression
programmed
death
ligand-1
(PD-L1),
which
inhibits
function,
downregulates
interferon
response,
strong
impact
on
regulation.
It
also
modulates
interleukin
secretion
influence
major
histocompatibility
complex
(MHC)
presentation.
In
addition
facilitating
persistent
immunoregulatory
have
significant
implications
evasion
response
tumor
This
review
dissects
through
avoids
cells
discusses
how
play
into
survival.
concludes
with
overview
cancer
treatments
targeting
setting
EBV-associated
malignancy.
Cancer Treatment and Research Communications,
Journal Year:
2024,
Volume and Issue:
43, P. 100880 - 100880
Published: Jan. 1, 2024
This
comprehensive
review
delves
into
the
intricate
role
of
programmed
cell
death
in
Epstein-Barr
virus
(EBV)-associated
malignancies,
focusing
on
sophisticated
interplay
between
viral
mechanisms
and
host's
immune
response.
The
central
objective
is
to
unravel
how
EBV
exerts
control
over
pathways
such
as
apoptosis,
ferroptosis,
autophagy,
thereby
fostering
its
persistence
oncogenic
potential.
By
dissecting
these
mechanisms,
seeks
identify
therapeutic
strategies
that
could
disrupt
EBV's
manipulation
pathways,
enhancing
recognition
opening
new
avenues
for
targeted
treatment.
A
deeper
understanding
molecular
underpinnings
influence
not
only
enriches
field
oncology
but
also
pinpoints
targets
drug
development.
Furthermore,
insights
gleaned
from
this
catalyze
design
vaccines
aimed
at
preventing
infection
or
curtailing
impact.
Innovatively,
synthesizes
recent
discoveries
multifaceted
roles
non-coding
RNAs
cellular
signaling
modulating
within
context
infection.
consolidating
current
knowledge
identifying
areas
where
lacking,
it
lays
groundwork
future
research
lead
significant
advancements
vaccine
development
interventions
EBV-related
cancers.
underscores
critical
necessity
ongoing
investigation
complex
host
with
ultimate
goal
patient
outcomes
EBV-associated
diseases.
Tumour Virus Research,
Journal Year:
2023,
Volume and Issue:
15, P. 200260 - 200260
Published: May 9, 2023
The
tegument
is
the
structure
between
envelope
and
nucleocapsid
of
herpesvirus
particles.
Viral
(and
cellular)
proteins
accumulate
to
create
layers
tegument.
Some
Epstein-Barr
virus
(EBV)
are
conserved
widely
in
Herpesviridae,
but
others
shared
only
by
members
gamma-herpesvirus
subfamily.
As
interface
nucleocapsid,
functions
virion
morphogenesis
budding
during
progeny
production.
When
a
particle
enters
cell,
enzymes
such
as
kinase
deubiquitinase,
transcriptional
activators
released
from
promote
infection.
Moreover,
some
EBV
involved
oncogenesis.
Here,
we
summarize
roles
proteins,
comparison
those
other
herpesviruses.
Epstein-Barr
virus
(EBV)
causes
multiple
human
cancers,
including
B-cell
lymphomas.
In
cell
culture,
EBV
converts
healthy
B-cells
into
immortalized
ones
that
grow
continuously,
which
model
post-transplant
Constitutive
signaling
from
two
cytoplasmic
tail
domains
of
the
oncogene
latent
membrane
protein
1
(LMP1)
is
required
for
this
transformation,
yet
there
has
not
been
systematic
analysis
their
host
gene
targets.
We
identified
only
proximal
domain
survival
these
EBV-immortalized
cells
and
its
loss
triggers
apoptosis.
key
LMP1
target
genes,
whose
abundance
changed
significantly
with
signals,
or
were
instead
upregulated
in
response
to
switching
on
by
one
both
an
EBV-uninfected
model.
These
included
major
anti-apoptotic
factors
necessary
EBV-infected
survival.
Bioinformatics
analyses
clusters
genes
respond
differently
either
domains.
Biology,
Journal Year:
2022,
Volume and Issue:
11(6), P. 799 - 799
Published: May 24, 2022
Epstein–Barr
virus
(EBV)
is
an
enveloped
DNA
that
belongs
to
the
gamma
Herpesviridae
family.
The
establishes
a
latent/lytic
persistent
infection,
though
it
can
be
involved
in
cancer
development
some
subjects.
Indeed,
evidence
supports
etiological
role
of
EBV
undifferentiated
nasopharyngeal
carcinoma
(NPC),
subset
gastric
carcinomas
and
lymphomas.
Additionally,
has
been
detected
breast
(BCs)
although
its
not
established.
In
this
review,
we
summarize
epidemiological
information
regarding
presence
BC
propose
mechanistic
models.
However,
additional
experimental
warranted
confirm
these
Frontiers in Immunology,
Journal Year:
2023,
Volume and Issue:
14
Published: Dec. 21, 2023
Epstein-Barr
virus
(EBV)
is
a
prevalent
oncogenic
estimated
to
infect
greater
than
90%
of
the
world's
population.
Following
initial
infection,
it
establishes
latency
in
host
B
cells.
EBV
has
developed
multitude
techniques
avoid
detection
by
immune
system
and
establish
lifelong
infection.
T
cells,
as
important
contributors
cell-mediated
immunity,
make
an
attractive
target
for
these
immunoevasive
strategies.
Indeed,
evolved
numerous
mechanisms
modulate
cell
responses.
For
example,
can
augment
expression
programmed
death
ligand-1
(PD-L1),
which
inhibits
function,
downregulates
interferon
response,
strong
impact
on
regulation.
It
also
modulates
interleukin
secretion
influence
major
histocompatibility
complex
(MHC)
presentation.
In
addition
facilitating
persistent
immunoregulatory
have
significant
implications
evasion
response
tumor
This
review
dissects
through
avoids
cells
discusses
how
play
into
survival.
concludes
with
overview
cancer
treatments
targeting
setting
EBV-associated
malignancy.
